Objective
Lung cancer is the most common cancer fatality in Europe (335000 deaths/yr). Non-small cell lung cancer (NSCLC) consists 85% of the cases, with 5 yr survival <15%. Hence, this proposal focuses on the urgent need for better NSCLC therapies. This is a European problem at societal and scientific level: better therapies are needed to keep the spiralling costs of European health systems under control, and the required expertise (basic science, clinical, biotech, experimental therapeutics) is scattered over the EU. Because of the diversity of the NSCLC problem (and the small/medium size of the project) we are focusing on two particular problems: 1) to find solutions for the currently clinically observed resistance problems with epidermal growth factor receptor (EGFR) targeting therapies (10% of NSCLC patients), and 2) to find a solution for the clinically unmet need for NSCLC patients with KRAS mutations (30% of NSCLC), for whom there virtually is no cure (besides very modest effects of platinum based therapies). Based on this focus, we assembled an EU wide consortium which joins excellent expertise at both the basic science (EGFR family, KRAS), clinical (involvement of several clinical study leaders) and biotech level (involvement of academic and SME biotech component). We aim:
1) To identify novel drug targets for the improvement of EGFR targeting therapies and for the development of therapies for K-Ras mutant patients (via genome wide RNAi screening and kinome/secretome profiling).
2) To validate these targets in innovative mouse models that replicate the clinical problem, and in patient materials (tissue and serum)
3) To develop novel therapeutics based on the unique expertise of our partners: anti-receptor DARPins (designed ankyrin repeat proteins), monoclonals or soluble receptors targeting the BROADER EGFR family (to block compensatory signalling), and protein kinase inhibitors
The results will have important basic scientific, clinical and economic impact
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences clinical medicine oncology lung cancer
- natural sciences chemical sciences inorganic chemistry transition metals
- natural sciences biological sciences biochemistry biomolecules proteins
- natural sciences biological sciences genetics mutation
- natural sciences biological sciences genetics genomes
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-HEALTH-2010-two-stage
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
3000 Leuven
Belgium
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.